Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense 365. The CE Mark submission aligns with the EU Medical Device Regulation (MDR ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

The US FDA warns users of smartphone-linked diabetes devices like CGMs and insulin pumps of potential health risks due to ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Shanghai's Ruijin Hospital announced today that researchers have developed a groundbreaking non-invasive blood glucose ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...

Shanghai researchers have devised a revolutionary, non-invasive method to monitor blood glucose, allowing for accurate blood ...

How the UAE uses AI-enabled medical care to better the lives of patients and optimises efficiencies in medicine with AI ...

U.S. officials are warning about a potentially life-threatening issue with smartphone apps that help manage diabetes.

Discover how the first FDA-approved over-the-counter continuous glucose monitor affects the wellness industry and its potential for early diabetes diagnoses.